Dose Escalation Study With 99mTC - or 186 Re-labelled Humanised Monoclonal Antibody (hMAb) BIWA 4 in Patients With Head and Neck Cancer
Phase 1
Completed
- Conditions
- Head and Neck Neoplasms
- Interventions
- Drug: 99mTc - labelled hMAb BIWA 4Drug: 186 Re - labelled hMAb BIWA 4Drug: unlabelled hMAb BIWA 4 - high doseDrug: unlabelled hMAb BIWA 4 - low doseDrug: unlabelled hMAb BIWA 4 - medium dose
- First Posted Date
- 2014-07-30
- Last Posted Date
- 2014-07-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 33
- Registration Number
- NCT02204033
Tolerability and Pharmacokinetics of Lacidipine With and Without the Co-administration of Telmisartan in Female and Male Healthy Subjects
- First Posted Date
- 2014-07-30
- Last Posted Date
- 2014-08-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 26
- Registration Number
- NCT02203500
Effect of Repeated Doses of BI 1060469 and BI 1021958 on Glomerular Filtration Rate (GFR) in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: PlaceboDrug: BI 1060469 high doseDrug: BI 1060469 low dose
- First Posted Date
- 2014-07-29
- Last Posted Date
- 2014-12-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 53
- Registration Number
- NCT02202512
- Locations
- 🇩🇪
1333.43.1 Boehringer Ingelheim Investigational Site, Berlin, Germany
Evolution of Pulse Pressure Following Initiation of Antihypertensive Therapy in Patients With Essential Arterial Hypertension
- First Posted Date
- 2014-07-29
- Last Posted Date
- 2014-07-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2148
- Registration Number
- NCT02202525
Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Phase 1
Completed
- Conditions
- Myelodysplastic SyndromesLeukemia, Myelomonocytic, Chronic
- Interventions
- First Posted Date
- 2014-07-28
- Last Posted Date
- 2018-07-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 5
- Registration Number
- NCT02201329
- Locations
- 🇯🇵
Boehringer Ingelheim Investigational Site, Tokyo, Sinagawa-ku, Japan
Pharmacovigilance and Patient Compliance in Hypertensive Patients
- First Posted Date
- 2014-07-25
- Last Posted Date
- 2014-07-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 10333
- Registration Number
- NCT02200575
Dose-escalation Study of BIBH 1 in Patients With Non-small Cell Lung Cancer Scheduled for Surgical Resection
- First Posted Date
- 2014-07-25
- Last Posted Date
- 2014-07-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 6
- Registration Number
- NCT02199886
A Trial Comparing MICARDIS® (Telmisartan) and COZAAR® (Losartan) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring (ABPM)
Phase 4
Completed
- Conditions
- Hypertension
- Interventions
- Drug: Low dose of Micardis®, once dailyDrug: Low dose of COZAAR®, once dailyDrug: High dose of Micardis®, once dailyDrug: High dose of COZAAR®, once dailyDrug: Placebo
- First Posted Date
- 2014-07-25
- Last Posted Date
- 2014-07-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 333
- Registration Number
- NCT02200640
Single Rising Dose Study Investigating the Safety, Tolerability and Pharmacokinetics of Spray Dried BIBN 4096 BS After Inhalation Administration in Healthy Male and Female Volunteers
- First Posted Date
- 2014-07-25
- Last Posted Date
- 2014-07-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 63
- Registration Number
- NCT02199860
Evaluation of the Effects of Pharmaton Tablets on Mental Performance and Physical Fatigue in Nurses Working Night Shift
Phase 2
Completed
- Conditions
- Sleep Disorders, Circadian Rhythm
- Interventions
- Drug: PlaceboDrug: Pharmaton® Caplets
- First Posted Date
- 2014-07-25
- Last Posted Date
- 2014-07-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 32
- Registration Number
- NCT02199847